🧾 What This Document Is

This is an 8-K filing, which is a report companies use to announce major news to investors. This specific filing announces a new, independent member joining Vaxart's Board of Directors. Think of it as an official press release filed with the SEC.

🏢 What The Company Does

👉 In simple terms, Vaxart is a biotech company trying to revolutionize vaccines by putting them in a pill instead of a shot.

They are a "clinical-stage" company, meaning they are still testing their vaccines in people and aren't selling any products yet. Their technology platform is designed to create oral vaccines that don't need refrigeration, which could make storage and distribution much easier globally. Their pipeline includes potential pill vaccines for coronavirus, norovirus, flu, and HPV.

👥 The New Board Member

Vaxart appointed James Breitmeyer, M.D., Ph.D., to its Board of Directors on April 23, 2026. Dr. Breitmeyer is not a newcomer to biotech; he has over 35 years of experience.

His key qualifications include:

• Led clinical programs that resulted in eight FDA product approvals.
• Has extensive experience with regulatory agencies in the U.S., Europe, and Japan.
• Most recently served as President and CEO of Oncternal Therapeutics, an oncology company.
• Was President of Bavarian Nordic, where he worked on vaccine development.
• Held senior roles at Eli Lilly and Cadence Pharmaceuticals.
• He is currently the CEO and Board Director of Altay Therapeutics.

🚀 Why This Appointment Matters

This hire is a strategic move to strengthen the board's expertise right as Vaxart pushes its vaccines through the difficult clinical trial phase.

👉 The key takeaway: Vaxart is bringing in a "regulatory and development guru." Dr. Breitmeyer's track record of guiding drugs through the FDA approval process is exactly what a clinical-stage company needs to navigate the path to potential commercialization. His vaccine experience from Bavarian Nordic is directly relevant.

🔮 What's Next for Vaxart

The appointment signals Vaxart is focused on the rigorous work of proving its vaccine platform. As stated in the release, Dr. Breitmeyer will help "advance our clinical programs" and "validate the unique advantages" of their technology. Investors will now watch for progress in their clinical trials for norovirus, flu, and HPV, with the expectation that this new board member's experience will guide those efforts.

⚖️ The Big Picture — Strengths & Risks

👍 Strengths / Positive Signals:

• Expertise Infusion: Adds proven, high-level clinical and regulatory knowledge to the board.
• Strategic Timing: Brings this experience in-house as the company advances its clinical programs, which is a critical and costly phase.
• Credibility: A board member with eight FDA approvals under his belt adds significant credibility to the company's scientific mission.

⚠️ Risks / Things to Watch:

• Still Early Stage: Vaxart remains a clinical-stage company with no approved products. This appointment doesn't change that fundamental risk.
• Execution is Key: The board provides guidance, but the company's success still depends on its science and clinical trial results. The expertise must translate into successful trials.
• Cash Runway: As with all clinical biotechs, the cost of advancing trials is high. Financial resources remain a critical factor.

🧠 The Analogy

Vaxart is like a promising shipbuilder that has designed an innovative new type of sail (the oral vaccine platform). They've now hired a seasoned captain (Dr. Breitmeyer) who has successfully navigated treacherous, uncharted waters (FDA approvals) multiple times before. The ship is still being built and hasn't set sail on its major voyage (Phase 3 trials) yet, but having this captain on board increases confidence in the journey ahead.

🧩 Final Takeaway

Vaxart is bolstering its leadership with a board member whose career is defined by getting drugs approved. This move is all about increasing the odds of successfully translating their promising science into a real, marketable product. It's a strategic hire for the challenging clinical phase ahead.

Contact for Inquiries: Vaxart Media and Investor Relations, [email protected]